Summary
To assess the extent of enterohepatic recycling of piroxicam and tenoxicam, their pharmacokinetics have been compared in the absence and presence of concomitant treatment with cholestyramine. In a randomized crossover study 6 healthy volunteers received piroxicam and tenoxicam 20 mg p.o., alone or with cholestyramine 24 g/day for 4 days.
Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively). It also increased the apparent clearance (Cl/f) of piroxicam and tenoxicam by 58% and 112%. When cholestyramine was administered, the t1/2 of piroxicam & tenoxicam were correlated (r=0.89), which suggests that their hepatic biotransformation is under a common control.
It is concluded that: piroxicam and tenoxicam are eliminated to a large and comparable extent through the biliary route, and the administration of cholestyramine may help to accelerate their elimination in cases of overdosage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ishizaki T, Nomura T, Abe T (1979) Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm 7: 369–381
Dupont D, Dayer P, Balant L, Gorgia A, Fabre J (1982) Variations inter-et intraindividuelles du comportement du piroxicam Pharmacocinétique chez l'homme en bonne santé et chez le malade en insuffisance rénale. Pharm Acta Helv 57: 20–26
Wiseman EH, Hobbs DC (1982) Review of pharmacokinetic studies with piroxicam. Am J Med 72 [Suppl 2A]: 9–17
Hobbs DC (1986) Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex and adverse effects. Am J Med 81 [Suppl 5B]: 22–28
Verbeeck RK, Richardson J, Blocka KLN (1986) Clinical pharmacokinetics of piroxicam. J Rheumatol 13: 789–796
Heintz RC, Guentert TW, Enrico HF, Dubach UC, Brandt R, Jeunet FS (1984) Pharmacokinetics of tenoxicam in healthy human volonteers. Eur J Rheum Inflam 7: 33–44
Bird HA, Allen JG, Dixon JS, Wright V (1985) A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. Br J Rheumatol 24: 351–356
Francis RJ, Allen JG, Looi D, Dixon JS, Bird HA, Wright V (1987) Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. Eur J Drug Metabol Pharmacokinet 12: 59–63
Guentert TW, Defoin R, Mosberg H (1988) The influence of colestyramine on the elimination of tenoxicam and piroxicam. Eur J Clin Pharmacol 34: 283–289
Nurnberg B, Brune K (1986) Analyse der biliären Elimination eines nichtsteroidalen Antirheumatikums (Diflunisal) bei Mensch und Hund. Akt Rheumatol 11: 116–120
Brune K, Nurnberg B (1987) The enterohepathic circulation of some anti-inflammatory drugs may cause intestinal ulcerations. In: Rainsford KD (ed) Side-effects of anti-inflammatory drugs. MTP Press, pp 29–39
Dixon JS, Lowe JR, Galloway DB (1984) Rapid method for the determination of either piroxicam or tenoxicam in plasma using high-performance liquid chromatography. J Chromatogr 310: 455–459
Fenner H, Stroiber W (1986) Tenoxicam, un nouveau médicament anti-inflammatoire non stéroïdien. Litera Rheumatol, Vol 6. EULAR
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benveniste, C., Striberni, R. & Dayer, P. Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. Eur J Clin Pharmacol 38, 547–549 (1990). https://doi.org/10.1007/BF00278579
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00278579